Hope Biosciences
Hope Biosciences is a biopharmaceutical company dedicated to developing and delivering adult stem cell solutions that are safe, effective, and affordable for incurable conditions. They focus on regenerative medicine, stem cell culture, banking, and therapeutics, with a mission to redefine disease treatment and prevention through innovative cell-based therapies. The company emphasizes quality, safety, and proprietary technology, and collaborates with academic and clinical research organizations to bring high-volume, consistent, and repeatable mesenchymal stem cells to patients. They are actively involved in FDA-authorized clinical trials for conditions such as COVID-19, multiple sclerosis, Alzheimer’s, traumatic brain injury, and more, and have received significant funding including a nearly $5 million Department of Defense grant for TBI research.
Industries
Nr. of Employees
small (1-50)
Hope Biosciences
Products
MSC-derived conditioned media (secretome)
Cell-culture-derived conditioned media containing proteins, cytokines, and growth factors collected from undifferentiated mesenchymal stem cell cultures for topical or research applications.
Topical serum formulated from conditioned media
Shelf-stable topical gel product formulated using MSC-conditioned media for topical skin applications.
Clinical-grade autologous MSC therapeutic doses
Individual therapeutic cell doses manufactured from a patient's own cultured mesenchymal stem cells for investigational use in clinical trials and expanded access, intended for intravenous administration.
MSC-derived conditioned media (secretome)
Cell-culture-derived conditioned media containing proteins, cytokines, and growth factors collected from undifferentiated mesenchymal stem cell cultures for topical or research applications.
Topical serum formulated from conditioned media
Shelf-stable topical gel product formulated using MSC-conditioned media for topical skin applications.
Clinical-grade autologous MSC therapeutic doses
Individual therapeutic cell doses manufactured from a patient's own cultured mesenchymal stem cells for investigational use in clinical trials and expanded access, intended for intravenous administration.
Services
Clinical-grade adult adipose-derived stem cell banking
Service to collect adipose tissue, isolate and expand mesenchymal stem cells, and establish master and working cell banks with clinical-grade testing and cryostorage.
Clinical-grade newborn placenta-derived stem cell banking
Processing and storage of placenta-derived tissue to isolate mesenchymal stem cells, create master cell banks, and store vials for potential future therapeutic manufacturing.
Clinical-grade manufacturing and supply of autologous MSC therapeutics
Manufacture of autologous mesenchymal stem cell therapeutic doses for use in clinical trials and expanded access, including multi-dose production, QC release, and shipment of fresh or cryopreserved doses to clinical sites.
Expanded access program operations
Management of expanded access requests through structured intake, clinical review, medical record assessment, and prioritization to facilitate investigational therapy access.
Conditioned media production and topical formulation services
Production of MSC-conditioned media and formulation into shelf-stable topical gel products for cosmetic or research applications.
Clinical-grade adult adipose-derived stem cell banking
Service to collect adipose tissue, isolate and expand mesenchymal stem cells, and establish master and working cell banks with clinical-grade testing and cryostorage.
Clinical-grade newborn placenta-derived stem cell banking
Processing and storage of placenta-derived tissue to isolate mesenchymal stem cells, create master cell banks, and store vials for potential future therapeutic manufacturing.
Clinical-grade manufacturing and supply of autologous MSC therapeutics
Manufacture of autologous mesenchymal stem cell therapeutic doses for use in clinical trials and expanded access, including multi-dose production, QC release, and shipment of fresh or cryopreserved doses to clinical sites.
Expanded access program operations
Management of expanded access requests through structured intake, clinical review, medical record assessment, and prioritization to facilitate investigational therapy access.
Conditioned media production and topical formulation services
Production of MSC-conditioned media and formulation into shelf-stable topical gel products for cosmetic or research applications.
Expertise Areas
- Autologous mesenchymal stem cell manufacturing and scale-up
- Clinical-grade stem cell banking for adults and newborns
- Clinical trial management and execution (Phase I–II/IIb, randomized and non-randomized designs)
- Regulatory submissions and FDA protocol compliance
Key Technologies
- Mesenchymal stem cell isolation and expansion
- Master cell bank and working cell bank generation
- Custom cell culture media and reagent systems
- Conditioned media / cell-secreted secretome processing